Orca-T

Phase I Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation From an HLA-Mismatched Donor (7/8) With Orca-T

What's the purpose of the trial?

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.
Trial status

Not yet accepting

Phase
Phase 1
Enrollment
24
Last Updated
2 months ago
Patient Screener

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Orca-T is a T cell therapy made from stem and T cells. Orca-T is made from allogeneic donors, and is specialized to try and minimize allogeneic transplant side effects. 
  • Ruxolitinib is a tyrosine kinase inhibitor in development for the treatment of several different blood cancers.
  • Tacrolimus is an immunosuppressive medication used to help prevent rejection in patients who have had a transplant.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.